BACKGROUND:

Testicular cancer is the most common solid tumor in men between 15 and 35 years of age. It represents 1% of all cancers in males, with a 0.2% lifetime risk for developing the disease.

AIMS:

To examine and describe the epidemiology and oncologic progression of testicular tumor in patients treated at our hospital.

MATERIALS AND METHODS:

An ambispective study was conducted on patients seen at the Hospital Militar Central within the time frame of January 2006 and October 2016. We conducted a retrospective analysis of the risk factors, tumor markers, tumor stage, international risk group classification, and treatment modality. The outcomes evaluated were recurrence-free survival and overall survival.

RESULTS:

The study included 115 patients. The most common histologic strain was seminoma (53.4%) and in the nonseminomatous tumors it was embryonal carcinoma. A total of 10.4% of the cases had a history of cryptorchidism. Eighty-five percent of the cases were low risk, 9% were intermediate risk, and 6% were high-risk. The initial treatment modality was orchiectomy plus active surveillance in 15 cases, orchiectomy plus radiotherapy in 19 cases, orchiectomy plus chemotherapy in 65 cases, and chemotherapy followed by orchiectomy in 2 cases. Three-year disease-free survival was 98% in the low-risk group, 87% in the intermediate-risk group, and 66.7% in the high-risk group. Overall 3-year survival was 99% for the lowrisk group, 100% for the intermediate-risk group, and 66.7% for the high-risk group (p<0.0001).

CONCLUSION:

Testicular tumor management should be multidisciplinary and based on the international risk group classification.

        · resumen en Español     · texto en Español     · Español ( pdf )